Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 157

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 157
---
In accordance with Israeli
law and practice and subject to the exemption set forth in NYSE American Section 110, we have elected to follow the provisions of
the Companies Law, rather than the NYSE American rules, with respect to the following requirements:

| ● | Quorum. While NYSE                                                                                                                         
 American Section 123 recommends a quorum of at least 33.33%, under Israeli law, a company is entitled to determine in its articles         
 of association the number of shareholders and percentage of holdings required for a quorum at a shareholders meeting. Our amended          
 and restated articles of association to be in effect upon completion of this offering provide that a quorum of two or more shareholders    
 holding at least 25% of the voting rights in person or by proxy is required for commencement of business at a general meeting. However,    
 the quorum set forth in our amended and restated articles of association with respect to an adjourned meeting consists of at least         
 one shareholder present in person or by proxy.                                                                                             |
| ● | Compensation of officers. Israeli                                                                                                          
 law and our amended and restated articles of association to be in effect upon completion of this offering do not require that the          
 independent members of our board of directors (or a compensation committee composed solely of independent members of our board of          
 directors) determine an executive officer’s compensation, as is generally required under NYSE American Section 805 with respect            
 to the chief executive officer and all other executive officers. Instead, compensation of executive officers is determined and approved    
 by our compensation committee and our board of directors, and in certain circumstances by our shareholders, either in consistency          
 with our office holder compensation policy or, in special circumstances in deviation therefrom, taking into account certain considerations 
 stated in the Companies Law. See “Management—Board Practices—Approval of Related Party Transactions under Israeli                          
 Law” for additional information.                                                                                                           |

| ● | Shareholder approval. We                                                                                                                        
 will seek shareholder approval for all corporate actions requiring such approval under the requirements of the Companies Law, rather            
 than seeking approval for corporation actions in accordance with NYSE American rules. In particular, under NYSE American 713, shareholder       
 approval is generally required for: (i) an acquisition of shares/assets of another company that involves the issuance of 20%                    
 or more of the acquirer’s shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest                    
 in the target company or the consideration to be received